Related Experiment Videos
Prostacyclin is a potent anti-mutagen
R Koratkar1, U N Das, P S Sagar
1Department of Medicine, Nizam's Institute of Medical Sciences, Hyderabad, India.
Prostaglandins, Leukotrienes, and Essential Fatty Acids
|February 1, 1993
Summary
Prostacyclin (PGI2) protects against genotoxicity from radiation and chemotherapy drugs like cis-DDP. This protective effect, lasting up to 24 hours, does not hinder chemotherapy
Area of Science:
- Pharmacology
- Toxicology
- Cancer Research
Background:
- Genotoxicity from chemotherapy and radiation poses a significant challenge in cancer treatment.
- Prostacyclin (PGI2) is a known vasodilator and inhibitor of platelet aggregation.
- The potential genoprotective effects of PGI2 against various mutagens were unexplored.
Purpose of the Study:
- To investigate the genoprotective potential of Prostacyclin (PGI2) against DNA damage induced by gamma-radiation, benzo(a)pyrene (BP), and cis-platinum (cis-DDP).
- To determine the duration of PGI2's genoprotective action.
- To elucidate the mechanisms underlying PGI2's genoprotective effects and assess its impact on the efficacy of cis-DDP chemotherapy.
Main Methods:
- Mice bone marrow cells were exposed to gamma-radiation, BP, or cis-DDP, with or without PGI2 or its analogue Carba-PGI2.
- Time-course studies were conducted to evaluate the duration of PGI2's protective effect.
- Mechanisms were investigated by assessing PGI2's effect on free radical generation and its interaction with 6-keto-PGF1 alpha and cyclic-AMP (c-AMP).
- Cytotoxicity of cis-DDP against Meth-A tumor cells was evaluated in vitro and in vivo in the presence of PGI2 and Carba-PGI2.
Main Results:
- PGI2 significantly prevented genetic damage in bone marrow cells induced by gamma-radiation, BP, and cis-DDP.
- Carba-PGI2 demonstrated efficacy against cis-DDP-induced mutagenicity.
- The genoprotective effect of PGI2 was observed to last for up to 24 hours.
- PGI2's protective action was not mediated by its metabolite 6-keto-PGF1 alpha, c-AMP, or free radical generation.
- PGI2 and Carba-PGI2 did not interfere with the tumoricidal action of cis-DDP against Meth-A tumor cells, both in vitro and in vivo.
Conclusions:
- PGI2 exhibits significant genoprotective properties against a range of damaging agents relevant to cancer therapy.
- The genoprotective mechanism of PGI2 does not involve free radical scavenging or modulation of the c-AMP pathway.
- PGI2 can be co-administered with chemotherapy agents like cis-DDP without compromising their anti-tumor efficacy.
- These findings support the development of novel cancer treatment strategies combining PGI2 with chemotherapeutic agents to mitigate normal tissue toxicity.